Search Results
Your search for L matches 3307 pages
Showing 2251 - 2300Novel Strategies Emerging for Triple-Negative Breast Cancer
Compelling hypotheses are emerging about the mechanisms driving triple-negative breast cancer, and they are driving drug development in this area, according to Joyce O’Shaughnessy, MD, Celebrating Women Chair of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center. She is also Medical...
Pazopanib of Benefit in Imatinib- and Sunitinib-Resistant GIST in French Phase II Trial
In a French phase II trial reported in The Lancet Oncology, Mir et al found that pazopanib (Votrient) plus best supportive care increased progression-free survival vs best supportive care in patients with advanced gastrointestinal stromal tumors (GIST) resistant to imatinib and sunitinib. Study...
Prognostic Scoring System for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
As reported in the Journal of Clinical Oncology, Shaffer et al have developed a prognostic scoring system for patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. Study Details The study involved data from 2,133 patients with myelodysplastic syndrome in...
In Early Brain Radiation Recovery Studies, Cranial Grafting of Stem Cell–Derived Therapy Improves Cognition and Reduces Neuropathology
While stem cells have shown promise for treating brain regions damaged by cancer radiation treatments, University of California, Irvine (UCI) researchers have found that microscopic vesicles isolated from these cells provide similar benefits without some of the risks associated with stem cells....
Phase Ib/II Study Reports High Response Rates Seen With Addition of Cisplatin to Regimen for Advanced Pancreatic Cancer
The oncology research team at HonorHealth Research Institute in Scottsdale, Arizona, is spearheading a phase Ib/II trial that is demonstrating promising results with a novel regimen in patients with advanced pancreatic cancer. “The patients we are treating have advanced adenocarcinoma of the...
Survival Period for Esophageal Cancer Is Tied to Race and Income
African American patients with esophageal cancer survive fewer months after diagnosis than white patients, but only if they also have low incomes, according to a study presented by Loretta Erhunmwunsee, MD, at the Annual Meeting of the Society of Thoracic Surgeons. Dr. Erhunmwunsee led the study...
Selected Abstracts From 2015 ASH Annual Meeting: Part 4
Here is the final installment of selected abstracts from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, focusing on Hodgkin lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. For other selected abstracts...
Jennie R. Crews, MD, FACP, Named President of the Association of Community Cancer Centers
Jennie R. Crews, MD, FACP, became the new President of the Association of Community Cancer Centers (ACCC) during the recent ACCC 42nd Annual Meeting in Washington, DC. Dr. Crews brings more than 18 years of experience in advancing quality oncology care, currently as the Medical Director for Cancer ...
Sarah L. Blair, MD, on Early-Stage Breast Cancer in Older Women: Surgical Management
Sarah L. Blair, MD, of UC San Diego Moores Cancer Center, discusses surgical resection of breast cancer, which has the best chance of cure and is better than hormonal treatment alone, even in patients over age 80.
Conquer Cancer Foundation Honors 74 Oncologists for Contributions to Genitourinary Cancer, Cancer Survivorship, Gastrointestinal Cancer, and Quality Care Research
The Conquer Cancer Foundation of ASCO is pleased to announce the recipients of its 2016 Conquer Cancer Foundation of ASCO Merit Awards in Gastrointestinal Cancer, Genitourinary Cancer, Cancer Survivorship, and Quality Care. The following 74 young investigators, recognized for the scientific merit...
Metastatic Breast Cancer With Discordant Tumors: Small Study Reports Treatment by Primary Status May Improve Survival
In a small retrospective series, patients with metastatic breast cancer treated according to the receptor status of the primary tumor, not the metastatic one, had significantly longer median overall survival. The study was reported at the 2016 Miami Breast Cancer Conference by T. Allen Pannell, Jr, ...
Trabectedin Improves Progression-Free Survival in Uterine Leiomyosarcoma
In women with uterine leiomyosarcoma, trabectedin (Yondelis), a novel cytotoxic agent, significantly improved progression-free survival, compared with dacarbazine (4.2 vs 1.5 months, hazard ratio [HR] = 0.55, P < .001). According to the study’s authors, a lack of cumulative toxicity allows...
Computer-Assisted Decision Support in Medical Oncology: We Need It Now
Today’s medical oncologist is increasingly challenged to stay current with the latest developments in cancer treatment. I have been fortunate to speak with many oncologists over the past quarter-century on how professional life has evolved since the 1990s. These conversations have left me with a...
Throwing Out the Baby With the Bathwater: A Critical Appraisal of the USPSTF Recommendation Against Screening for Prostate Cancer
In 2012, the U.S. Preventive Services Task Force (USPSTF) issued a recommendation against routine screening for prostate cancer.1,2 The grade D recommendation was considered controversial at the time, and remains so now, because many stakeholders have weighed the same body of evidence and come to...
The POPLAR Trial: PD-L1 Blockade With Atezolizumab in Second- or Third-Line Non–Small Cell Lung Cancer
The randomized phase II POPLAR trial—reported by Fehrenbacher and colleagues and reviewed in this issue of The ASCO Post—is another key piece of information for the medical community regarding the value of immune checkpoint blockers in second/third-line treatment of patients with non–small cell...
Atezolizumab Improves Survival vs Docetaxel in Previously Treated NSCLC: Increased Benefit With Increased PD-L1 Expression
In the phase II POPLAR trial reported in The Lancet, Louis Fehrenbacher, MD, of Kaiser Permanente Medical Center, and colleagues found that the investigational anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab improved overall survival vs docetaxel in patients with non–small cell...
Low-Magnitude, High-Frequency Mechanical Stimulation May Improve Bone Mineral Density in Young Childhood Cancer Survivors
In a small trial reported in JAMA Oncology, Mogil et al found that low-magnitude, high-frequency mechanical stimulation improved the whole-body bone mineral density score in childhood cancer survivors with low bone mineral density. Study Details In the double-blind trial, 65 survivors of...
Minimal Residual Disease in AML: Worth Looking?
As summarized in this issue of The ASCO Post, Ivey and colleagues demonstrated that assessing for NPM1-mutated gene transcripts by reverse-transcriptase quantitative polymerase chain reaction assay is a feasible approach for measuring minimal residual disease after acute myeloid leukemia (AML)...
Study Shows Breast-Conserving Therapy Beats Mastectomy, but Questions Remain
Breast-conserving therapy (lumpectomy plus radiation therapy) appears to improve 10-year overall survival for women with early breast cancer compared with mastectomy, according to a very large population-based study from the Netherlands.1 However, the study raises more questions than it answers,...
‘Know Your Tumor’ Program Aids Patients With Pancreatic Cancer
Patients with pancreatic cancer can obtain molecular tumor profiling through the Pancreatic Cancer Action Network’s Know Your TumorSM precision medicine initiative, a partnership with Perthera, a personalized medicine service company that facilitates the multi-omic profiling and generates the...
Studies Evaluate Bevacizumab-Containing Regimens in Metastatic Colorectal Cancer
Two trials reported at the 2016 Gastrointestinal Cancers Symposium evaluated bevacizumab (Avastin)-containing regimens in the first-line treatment of metastatic colorectal cancer and supported some, but not all, previous findings. The STEAM trial found some numerical differences but no...
The Time Is Now for the Worldwide Cancer Community to Be Proactive
The ASCO Post recently spoke with nationally recognized surgical oncologist Chandrakanth Are, MBBS, MBA, FRCS, FACS, Jerald L & Carolynn J. Varner Professor of Surgical Oncology & Global Health; Vice Chair of Education; and Program Director, General Surgery Residency, University of Nebraska ...
Introduction of New Diagnostic Devices in Oncology: New Is Not Necessarily Better
“New!” “Improved!” “Throw out that old [fill in the blank] and go buy a new [fill in the blank]!” Sound familiar? The key to marketing is to convince customers that they need a product without which they had previously been quite happy. All too often, this strategy is accompanied by a caveat emptor ...
How Rehabilitation Services Provide Benefit for Patients With Spinal Metastases
The benefits of rehabilitation in traumatic spinal injuries are well established. Recently, studies have shown similarly positive results in cancer-related spinal injuries, indicating that rehabilitation can play a complementary role in the care management of this patient population....
Closing the Clinical Trial Gap for Adolescents and Young Adults With Cancer
Although overall survival rates for patients with cancer continue to soar—with 14.5 million cancer survivors today1—most of that gain is among pediatric and older adult patients. For adolescents and young adults with cancer—defined by the National Cancer Institute (NCI) as those in the 15- to...
Geriatric Assessment of Transplant-Ineligible Older Adults With Multiple Myeloma: A Novel Approach in the Era of Novel Agents
Myeloma is a disease of aging, with a median age at diagnosis in the United States of 69 years.1 As the population ages, forecasts estimate that, within 20 years, 3 of every 4 people diagnosed with multiple myeloma in the United States will be between the ages of 64 and 84 years.2 In anticipation...
Obinutuzumab in Relapsed or Refractory Follicular Lymphoma
On February 26, 2016, obinutuzumab (Gazyva) was approved for use in combination with bendamustine (Bendeka, Treanda) followed by obinutuzumab monotherapy for treatment of patients with follicular lymphoma who have relapsed after or are refractory to a rituximab (Rituxan)-containing regimen.1,2...
Two Types of Asparaginase Compared in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia
Intravenous pegylated (PEG) Escherichia coli (E coli) asparaginase was associated with similar toxicity and efficacy compared with intramuscular native E coli L-asparaginase in children with newly diagnosed acute lymphoblastic leukemia, according to the results of a phase III trial (DFCI 05-001).1 ...
Cancer Survivorship Research: Learning From the Past to Improve Future Outcomes
Soon after effective therapies for some childhood malignancies were first identified, early leaders in our field had concerns about what would happen to surviving patients as they aged. In 1975, Giulio D’Angio, MD, one of the founders of modern pediatric radiation oncology, presciently called for...
Two Fellows Selected for ASCO’s Inaugural Health Policy Fellowship Program
ASCO has announced the two physicians selected for its new Health Policy Fellowship, which kicked off this past October. Robert M. Daly, MD, and Steve Y. Lee, MD, will be the fellows for the inaugural class, which runs from July 1, 2016, to July 1, 2017. The program, aimed at oncologists in the...
‘Red-Flag’ Symptoms That Could Signal Colorectal Cancer in Patients Under 50 Years Old Should Be Taken Seriously
In clinical practice, Samantha Hendren, MD, MPH, has been “shocked by what a large proportion of patients we are seeing who are under 50 and presenting with colorectal cancer,” often with advanced disease due to delayed diagnosis. “And that is because patients and physicians don’t even think of...
Expert Point of View: C. Kent Osborne, MD
“We used to consider HER2-positive breast cancer one of the more aggressive forms of the disease. Now we have treatments based on HER2 expression that have dramatically altered the course of the disease for many patients,” said C. Kent Osborne, MD, who moderated the press conference where these...
2015 Palliative Care in Oncology Symposium Highlights
The Palliative Care in Oncology Symposium, held October 9–10, 2015, in Boston, Massachusetts, brought together more than 670 members of the cancer care community, including oncologists, radiologists, palliative care specialists, nurses, and patient advocates. Sessions delivered information on...
Carfilzomib Plus Dexamethasone in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 21, 2016, carfilzomib (Kyprolis) was approved for use in ...
PET Scan Use in Follow-up Care for Lung and Esophageal Cancer Shows Wide Variation Between Hospitals, No Impact on Survival
A new study suggests that one approach to watching for a cancer's return is being inappropriately used at many hospitals and isn't helping patients survive longer. The findings are published by Healy et al in the Journal of the National Cancer Institute. The study looked at how often survivors ...
Sandra L. Wong, MD's, Oral Abstract Discussion: Expert Perspective
Sandra L. Wong, MD, of the Dartmouth-Hitchcock Medical Center, summarizes three abstracts for which she was the discussant. The topics were rates of surgical site infections, an online resource for hospital cancer surgery volumes, and barriers to oncology appointments at comprehensive cancer...
Dawn L. Hershman, MD, on Improving Quality and Safety With Multidisciplinary Teams
Dawn L. Hershman, MD, of Columbia University Medical Center, summarizes a joint ASCO/NCI session on this important topic, including the challenges and solutions.
ASCO Commends Confirmation of Robert M. Califf, MD, as FDA Commissioner
“We commend the U.S. Senate for confirming Robert M. Califf, MD, as Commissioner of the Food and Drug Administration (FDA). Dr. Califf brings extraordinary expertise and vision to this position and we are confident that his appointment will positively impact cancer care. “Dr. Califf's...
Mistletoe
The use of dietary supplements by patients with cancer has increased significantly over the past 20 years despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and...
Failure of Updated Dietary Guidelines to Advise Limiting Red and Processed Meat Deemed a ‘Missed Opportunity’
“A missed opportunity” is how Susan Higginbotham, PhD, RD, Vice President for Research, American Institute for Cancer Research (AICR), described the “failure” of updated dietary guidelines to recommend limiting consumption of red and processed meat. Doing so would have “the potential to save...
Selected Abstracts From 2015 ASH Annual Meeting: Part 3
Here are several more abstracts selected from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, focusing on newly diagnosed multiple myeloma, relapsed/refractory multiple myeloma, and amyloid light-chain (AL) amyloidosis. For other selected abstracts...
ASCO Announces New Award Recognizing Extraordinary Contributions to Cancer Survivorship Care
ASCO has announced the creation of the Ellen L. Stovall Award and Lecture for Advancement of Cancer Survivorship Care, intended to recognize and promote the work of pioneers and leaders in the growing field of survivorship. The first award will be presented at the 2017 Cancer Survivorship...
Candid Discussions on Living With and After Cancer at An Evening for Cancer Survivors and Caregivers
On January 14, 2016, the Cancer Survivorship Symposium opened with An Evening for Cancer Survivors and Caregivers, an event featuring networking, a panel discussion, and an open forum to share the challenges of living with or after a cancer diagnosis. The audience included Symposium attendees as...
Rolapitant Reduces Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately and Highly Emetogenic Chemotherapy
In three phase III studies reported in The Lancet Oncology, the addition of the neurokinin-1 (NK-1) receptor antagonist rolapitant to serotonin (5-HT3) receptor antagonist and dexamethasone treatment significantly improved complete response rates in the prevention of chemotherapy-induced nausea and ...
Management of Advanced Lung Cancer in the Elderly: A Reason to Rejoice or a Cause for Concern?
There is ample evidence to suggest that older adults with a good performance status (0 or 1) with advanced non–small cell lung cancer (NSCLC) should be treated with combination chemotherapy akin to younger patients.1,2 However, older adults comprise a heterogeneous group that has been...
Ofatumumab for Extended Treatment of Patients With Recurrent or Progressive Chronic Lymphocytic Leukemia
On January 19, 2016, ofatumumab (Arzerra) was approved for extended treatment of patients in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL).1,2 Ofatumumab was previously approved for treatment of untreated patients...
David J. McConkey, PhD, Named Director of Johns Hopkins Greenberg Bladder Cancer Institute
David J. McConkey, PhD, has been appointed Director of the Johns Hopkins Greenberg Bladder Cancer Institute. The institute was established in 2014 with a $15 million gift from Baltimore-area commercial real estate developer Erwin L. Greenberg and his wife, Stephanie Cooper Greenberg, and a $30...
Genomic, Molecular Differences in Tumor Biology May Explain Inferior Survival in African Americans With Kidney Cancer
African Americans who develop metastatic renal cell carcinoma have had worse survival historically than whites. With the advent of targeted therapy, the hope is that the gap in survival would be narrowed. However, a new study has shown that survival for African Americans with metastatic renal cell...
Clinic-Based Weight-Loss Intervention Successful in Cancer Survivors
A randomized clinical trial examining the effect of a 15-week healthy living program on weight loss in cancer survivors showed a 5.3% decrease in baseline body weight in those participating in the program.1 “Cancer survivors randomized to a 15-week clinic-based weight-loss intervention lost an...
Detection of Thyroid Cancer Most Cost-Effective With Physical Examination, Not Ultrasound Screening
A study evaluating annual physical examination as a screening method to detect thyroid cancer in cancer survivors exposed to neck radiation has shown a substantial cost reduction compared with ultrasound screening, with no thyroid cancer–related mortality.1 According to the analysis, this method...
